Items where Author is "Wagner, Anita K."

Number of items: 10.
Article
  • Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe:lessons for the accelerated approval pathway. (2024) Shahzad, Mahnum and Naci, Huseyin and Esselen, Katharine M. and Dottino, Joseph A. and Wagner, Anita K. picture_as_pdf
  • Overall survival benefits of cancer drugs approved in China from 2005 to 2020. (2022) Zhang, Yichen and Naci, Huseyin and Wagner, Anita K. and Xu, Ziyue and Yang, Yu and Zhu, Jun and Ji, Jiafu and Shi, Luwen and Guan, Xiaodong picture_as_pdf
  • Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. Shahzad, Mahnum and Naci, Huseyin and Wagner, Anita K.
  • Cancer drug indication approvals in China and the United States:a comparison of approval times and clinical benefit, 2001–2020. Wei, Yuxuan and Zhang, Yichen and Xu, Ziyue and Wang, Guoan and Zhou, Yue and Li, Huangqianyu and Shi, Luwen and Naci, Huseyin and Wagner, Anita K. and Guan, Xiaodong picture_as_pdf
  • Communication of anticancer drug benefits and related uncertainties to patients and clinicians:document analysis of regulated information on prescription drugs in Europe. Davis, Courtney and Wagner, Anita K. and Salcher-Konrad, Maximilian and Scowcroft, Henry and Mintzes, Barbara and Pokorny, Adrian M J and Lew, Jianhui and Naci, Huseyin picture_as_pdf
  • Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. Naci, Huseyin and Guan, Xiaodong and Woloshin, Steven and Xu, Ziyue and Wagner, Anita K. picture_as_pdf
  • Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil:a retrospective analysis. Ivama-Brummell, Adriana M. and Marciniuk, Fernanda L and Wagner, Anita K. and Osorio-de-Castro, Claudia G. S. and Vogler, Sabine and Mossialos, Elias and Tavares-de-Andrade, Carla L. and Naci, Huseyin picture_as_pdf
  • Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data:a retrospective analysis. Naci, Huseyin and Zhang, Yichen and Woloshin, Steven and Guan, Xiaodong and Xu, Ziyue and Wagner, Anita K. picture_as_pdf
  • Patients deserve better information on new drugs. Davis, Courtney and Wagner, Anita K. and Mintzes, Barbara and Scowcroft, Henry and Woloshin, Steven and Naci, Huseyin
  • Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. Fu, Mengyuan and Naci, Huseyin and Booth, Christopher M. and Gyawali, Bishal and Cosgrove, Austin and Toh, Sengwee and Xu, Ziyue and Guan, Xiaodong and Ross-Degnan, Dennis and Wagner, Anita K.